Potential of fecal carcinoembryonic antigen for noninvasive detection of colorectal cancer: a systematic review
Carcinoembryonic antigen (CEA) is more abundant in feces than in serum; however, evidence for the role of fecal CEA (FCEA) in the detection of colorectal cancer (CRC) is limited. We conducted a systematic review of studies that evaluated FCEA for the noninvasive detection and diagnosis of CRC. PubMe...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
30 November 2023
|
| In: |
Cancers
Year: 2023, Volume: 15, Issue: 23, Pages: 1-12 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers15235656 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers15235656 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/15/23/5656 
|
| Author Notes: | Xianzhe Li, Lara Stassen, Petra Schrotz-King, Zitong Zhao, Rafael Cardoso, Janhavi R. Raut, Megha Bhardwaj and Hermann Brenner |
| Summary: | Carcinoembryonic antigen (CEA) is more abundant in feces than in serum; however, evidence for the role of fecal CEA (FCEA) in the detection of colorectal cancer (CRC) is limited. We conducted a systematic review of studies that evaluated FCEA for the noninvasive detection and diagnosis of CRC. PubMed and Web of Science were searched for relevant studies published until 18 January 2023. Information on publication year, study design, country, study population characteristics, FCEA and serum CEA (SCEA) concentrations, and diagnostic performance was summarized. Two authors independently extracted data and assessed the risk of bias and applicability of each included study. Seven studies published between 1979 and 2021, all conducted in clinical settings and together involving 399 CRC patients and 889 controls, were identified. Significant differences in FCEA concentrations were observed between CRC and control groups in all studies. Methods for detecting FCEA varied, with the electronic chemiluminescence immunoassay (ECLIA) being used in the most recent studies. Reported sensitivities, specificities, and area under the curves of FCEA ranged from 50.0% to 85.7%, 73.0% to 100.0%, and 0.704 to 0.831, respectively. In direct comparisons, the diagnostic performance of FCEA was better than that of SCEA. The potential role of FCEA as a novel, noninvasive, easily measurable biomarker for the diagnosis of CRC requires further evaluation in screening settings. |
|---|---|
| Item Description: | Gesehen am 26.01.2024 |
| Physical Description: | Online Resource |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers15235656 |